Skip to main content
OpenTrials
Completed

NCT Number: NCT04855305

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

The purpose of this multi-centered, NIH-sponsored study is to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Duke University Medical Center

Durham, North Carolina, 27710, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion/Exclusion Criteria for Healthy Volunteers

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:

  • Outpatients of either gender, age greater than or equal to 18 years
  • Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
  • Subject has no diagnosed pulmonary conditions
  • Subject has not smoked in the previous 5 years
  • Smoking history, if any, is less than or equal to 5 pack-years
  • No history of using other inhaled products more than 1 time per week for > 1 year

Exclusion criteria

Subjects presenting with any of the following will not be included in the trial:

  • Subject is less than 18 years old
  • MRI is contraindicated based on responses to MRI screening questionnaire
  • Subject is pregnant or lactating
  • Resting oxygen saturation on room air <90%
  • Respiratory illness of a bacterial or viral etiology within 30 days of MRI
  • Subject has history of any known ventricular cardiac arrhythmia
  • Subject has history of cardiac arrest within the last year
  • Subject does not fit into Xe vest coil used for MRI 129
  • Subject cannot hold his/her breath for 15 seconds
  • Subject deemed unlikely to be able to comply with instructions during imaging
  • Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Inclusion/Exclusion Criteria for Subjects with Interstitial Lung Disease

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the trial:

  • Outpatients of either gender, age greater than or equal to 18 years
  • Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
  • Clinical diagnosis of Interstitial Lung Disease made by a board certified pulmonologist using established criteria. We will not exclude individuals based on ILD type or severity of disease with the exception of the below criteria

Exclusion criteria

Subjects presenting with any of the following will not be included in the trial:

  • Subject is less than 18 years old
  • MRI is contraindicated based on responses to MRI screening questionnaire
  • Subject is pregnant or lactating
  • Resting oxygen saturation <90% on supplemental oxygen
  • Respiratory illness of a bacterial or viral etiology within 30 days of MRI
  • Subject has history of any known ventricular cardiac arrhythmia.
  • Subject has history of cardiac arrest within the last year
  • Subject does not fit into Xe vest coil used for MRI 129
  • Subject cannot hold his/her breath for 15 seconds
  • Subject deemed unlikely to be able to comply with instructions during imaging
  • Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Treatment and study plan

Hyperpolarized 129Xe

Drug

Hyperpolarized 129Xe will be administered in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.

Primary outcomes

  1. Thoracic Cavity Volume Measured in Liters

    Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)

  2. RBC/Barrier Signal Ratio (Unitless).

    Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)

    The RBC/Barrier Signal Ratio is a key quantitative metric in hyperpolarized Xe MRI that measures lung function by comparing the xenon signal in red blood cells (RBCs) to the signal in the pulmonary interstitial membrane (blood-gas barrier). It directly reflects how effectively xenon transfers across the membrane into the blood, with lower ratios indicating impairment in conditions like pulmonary fibrosis. For healthy individuals, this ratio is typically around a median (1Q-3Q) of 0.51 (0.45 - 0.57), while in subjects with pulmonary fibrosis, it can be significantly lower (e.g., 0.23 (0.21-0.24)).

  3. Coefficient of Repeatability of RBC/Barrier Signal Ratio (Unitless).

    Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)

    A measure of how much maximum change in the RBC:Barrier is expected due to experimental variability. The coefficient of repeatability is calculated as 1.96 times the standard deviation observed in the RBC/barrier signal ratio.

  4. Echo Time to Separate RBC and Barrier Signals by 90 Degrees (ms).

    Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)

  5. Population-wide RBC/Barrier Signal Ratio (Unitless).

    Time frame: 1 day (immediately after administration of hyperpolarized 129 Xenon)

    The RBC/Barrier Signal Ratio is a key quantitative metric in hyperpolarized Xe MRI that measures lung function by comparing the xenon signal in red blood cells (RBCs) to the signal in the pulmonary interstitial membrane (blood-gas barrier). It directly reflects how effectively xenon transfers across the membrane into the blood, with lower ratios indicating impairment in conditions like pulmonary fibrosis. For healthy individuals, this ratio is typically around a median (1Q-3Q) of 0.51 (0.45 - 0.57), while in subjects with pulmonary fibrosis, it can be significantly lower (e.g., 0.23 (0.21-0.24)).

Sponsors and collaborators

Lead sponsor

Bastiaan Driehuys

Other

Collaborators

  • Children's Hospital Medical Center, Cincinnati
  • National Heart, Lung, and Blood Institute (NHLBI)
  • University of Cincinnati
  • University of Iowa

Registry information

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Apr 22, 2021
Registry last updated
Aug 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.